191 patents
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
9 Jan 24
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after restimulation.
Ian Frank, Michael T. Lotze
Filed: 15 Aug 22
Utility
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
9 Jan 24
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Cecile Chartier-Courtaud, Krit Ritthipichai
Filed: 1 Jul 22
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
2 Jan 24
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 11 Aug 22
Utility
Methods of Using Tumor Infiltrating Lymphocytes In Double-refractory Melanoma
28 Dec 23
Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed.
Maria FARDIS
Filed: 11 Sep 23
Utility
Til Expansion Processes Using Specific Cytokine Combinations And/or Akti Treatment
28 Dec 23
Provided herein are methods of producing TILs via (i) pre-REP stimulation with a combination of interferon gamma (IFNγ) and an anti-PD-1 antibody, with or without a CD40 agonist, and with or without an anti-CTLA-4 antibody (ii) various concentrations of IL-15 and IL-21, with or without low-concentration IL-2, with or without an AKT inhibitor (AKTi) during REP expansion and/or pre-REP expansion, (iii) low-concentration IL-2 and an AKTi during REP expansion and/or pre-REP expansion, (iv) the combination of (i) and (ii), or (v) the combination of (i) and (iii).
Tim ERICKSON, Andrew YUHAS, Rafael CUBAS
Filed: 20 Jun 23
Utility
Cell Culture System and Methods of Using the Same
7 Dec 23
A gas permeable cell culture device including a container body defining an interior volume, the container body having a semi-permeable membrane defining one end of the interior volume, a fitting defining an opposing end of the interior volume, and a cell transfer conduit.
Seth Wardell, Joseph James Wypych
Filed: 22 Oct 21
Utility
Treatment of NSCLC Patients with Tumor Infiltrating Lymphocyte Therapies
23 Nov 23
The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody and/or anti-PD-L1 antibody and/or VEGF inhibitor, or wherein the NSCLC has a predetermined tumor proportion score (TPS).
Maria FARDIS, Friedrich Graf Finck VON FINCKENSTEIN
Filed: 6 Oct 21
Utility
Treatment of NSCLC Patients with Tumor Infiltrating Lymphocyte Therapies
23 Nov 23
The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody and/or anti-PD-LI antibody and/or VEGF inhibitor, or wherein the NSCLC has a predetermined tumor proportion score (TPS).
Maria FARDIS, Friedrich Graf Finck VON FINCKENSTEIN
Filed: 15 Oct 21
Utility
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
21 Nov 23
Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed.
Maria Fardis
Filed: 5 Jun 18
Utility
Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood
26 Oct 23
Methods of expanding tumor infiltrating lymphocytes (TILs), including peripheral blood lymphocytes (PBLs) and marrow infiltrating lymphocytes (MILs), from blood and/or bone marrow of patients with hematological malignancies, such as liquid tumors, including lymphomas and leukemias, and genetic modifications of expanded TILs, PBLs, and MILs to incorporate chimeric antigen receptors, genetically modified T-cell receptors, and other genetic modifications, and uses of such expanded and/or modified TILs, PBLs, and MILs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.
Lavakumar Karyampudi, Maria Fardis
Filed: 13 Mar 23
Utility
Selection of Improved Tumor Reactive T-cells
21 Sep 23
The present invention provides methods for preselecting TILs based on PD-1, CD39, CD38, CD103, CD101, LAG3, TIM3 and/or TIGIT expression, as well as methods for expanding those preselected PD-1, CD39, CD38, CD103, CD101, LAG3, TIM3 and/or TIGIT positive TILs in order to produce therapeutic populations of TILs with enhanced tumor-specific killing capacity (e.g., enhanced cytotoxicity).
Michelle Simpson-Abelson, Arvind Natarajan
Filed: 4 May 21
Utility
Processes for generating TIL products enriched for tumor antigen-specific T-cells
1 Aug 23
The present invention provides improved and/or shortened processes and methods for reprogramming TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy.
Cecile Chartier-Courtaud, Krit Ritthipichai
Filed: 4 May 22
Utility
Expansion of Tumor Infiltrating Lymphocytes with Potassium Channel Agonists and Therapeutic Uses Thereof
6 Jul 23
Methods of expanding tumor infiltrating lymphocytes (TILs) using a potassium channel agonist, such as a KCa3.1 (IK channel) agonist, and uses of such expanded TILs in the treatment of diseases such as cancer are disclosed herein.
Krit RITTHIPICHAI, Michael T. LOTZE
Filed: 10 Jun 22
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
16 May 23
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
4 May 23
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 1 Jul 22
Utility
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
18 Apr 23
A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient.
Anne Brooks, Steve Macrides, Kristin Lanzi
Filed: 6 Jan 22
Utility
Remnant Tumor Infiltrating Lymphocytes and Methods of Preparing and Using the Same
6 Apr 23
In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.
Michelle R. Simpson-Abelson, Christopher Mosychuk, Michael T. Lotze
Filed: 9 Jun 22
Utility
Expansion of Tumor Infiltrating Lymphocytes from Liquid Tumors and Therapeutic Uses Thereof
23 Mar 23
Methods of expanding tumor infiltrating lymphocytes (TILs), including peripheral blood lymphocytes and marrow infiltrating lymphocytes, from blood and/or bone marrow of patients with hematological malignancies, such as liquid tumors, including lymphomas and leukemias, and uses of such expanded TILs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.
Lavakumar Karyampudi, Maria Fardis
Filed: 12 Jul 22
Utility
CorrectedProcesses for Generating Til Products Enriched for Tumor Antigen-specific T-cells
23 Feb 23
The present invention provides improved and/or shortened processes and methods for reprogramming TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy.
Cecile CHARTIER-COURTAUD, Krit RITTHIPICHAI
Filed: 4 May 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
16 Feb 23
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22